[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @AscendingBio AscendingBio AscendingBio posts on X about $akba, future, in 2026, $kura the most. They currently have XXX followers and XX posts still getting attention that total XX engagements in the last XX hours. ### Engagements: XX [#](/creator/twitter::1883175331747479552/interactions)  - X Week XXXXX -XX% - X Month XXXXXX -XX% - X Months XXXXXXX +73% ### Mentions: X [#](/creator/twitter::1883175331747479552/posts_active)  - X Week XX -XX% - X Month XX +5.60% - X Months XXX +106% ### Followers: XXX [#](/creator/twitter::1883175331747479552/followers)  - X Week XXX +7.40% - X Month XXX +15% - X Months XXX +151% ### CreatorRank: undefined [#](/creator/twitter::1883175331747479552/influencer_rank)  ### Social Influence **Social category influence** [cryptocurrencies](/list/cryptocurrencies) XXXX% **Social topic influence** [$akba](/topic/$akba) #1, [future](/topic/future) 15.38%, [in 2026](/topic/in-2026) 7.69%, [$kura](/topic/$kura) 7.69%, [market cap](/topic/market-cap) 7.69%, [$4151t](/topic/$4151t) 7.69%, [$2503t](/topic/$2503t) 7.69%, [$rare](/topic/$rare) 7.69%, [$mreo](/topic/$mreo) 7.69%, [$crdf](/topic/$crdf) XXXX% **Top accounts mentioned or mentioned by** [@stocksdd](/creator/undefined) [@kellymetz2000](/creator/undefined) [@sammy191189](/creator/undefined) [@nxus9488676607](/creator/undefined) [@mamdouhameen90](/creator/undefined) [@notechnicals](/creator/undefined) [@chris83489710](/creator/undefined) **Top assets mentioned** [SuperRare (RARE)](/topic/$rare) ### Top Social Posts Top posts by engagements in the last XX hours "$AKBA The Q32 Bio version of the announcement of the sale of ADX-097 had a few more details: "Akebia has acquired ADX-097 and will be responsible for future development and commercialization. Under the terms of the agreement Q32 Bio will receive $XX million in upfront payments and a near-term milestone which includes $X million received at signing $X million at the 6-month anniversary of signing and $X million payable upon the earlier of the achievement of a milestone or the end of 2026. These payments as well as potential development regulatory and commercial milestones total up to $592" [X Link](https://x.com/AscendingBio/status/1995504842261807269) 2025-12-01T14:46Z XXX followers, XXX engagements "$AKBA Why acquire ADX-097 given the expenses Here is what I expect them to convey related to funding: We want to continue developing new kidney disease drugs. At this junction we do not have large amounts of capital. ADX-097 was sold to us at a low price. Research expenses will be modest in 2026. What helps keep those expenses low is that the FDA does not require large sample sizes for rare diseases. This drug may have some application to conditions that are not rare but that will not be our initial focus" [X Link](https://x.com/AscendingBio/status/1995528889750438058) 2025-12-01T16:22Z XXX followers, XXX engagements "$KURA Cash vs. Market Cap At last quarterly reported $XXXXX million in cash. Today announced a $XXX million payment from Kyowa Kirin. Market Cap is about XXX million" [X Link](https://x.com/AscendingBio/status/1995921283691810829) 2025-12-02T18:21Z XXX followers, XXX engagements "$RARE $MREO Timeline for Data Unchanged Data release: "Around end of year - defined as December or January"" [X Link](https://x.com/AscendingBio/status/1995950963577000119) 2025-12-02T20:19Z XXX followers, XXX engagements "$CRDF Results from Investigator-led (not company) Trial Positive monotherapy results yet the future will likely focus on use in combo treatment" [X Link](https://x.com/AscendingBio/status/1998140368039329995) 2025-12-08T21:19Z XXX followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@AscendingBio AscendingBio
AscendingBio posts on X about $akba, future, in 2026, $kura the most. They currently have XXX followers and XX posts still getting attention that total XX engagements in the last XX hours.
Engagements: XX #
- X Week XXXXX -XX%
- X Month XXXXXX -XX%
- X Months XXXXXXX +73%
Mentions: X #
- X Week XX -XX%
- X Month XX +5.60%
- X Months XXX +106%
Followers: XXX #
- X Week XXX +7.40%
- X Month XXX +15%
- X Months XXX +151%
CreatorRank: undefined #
Social Influence
Social category influence cryptocurrencies XXXX%
Social topic influence $akba #1, future 15.38%, in 2026 7.69%, $kura 7.69%, market cap 7.69%, $4151t 7.69%, $2503t 7.69%, $rare 7.69%, $mreo 7.69%, $crdf XXXX%
Top accounts mentioned or mentioned by @stocksdd @kellymetz2000 @sammy191189 @nxus9488676607 @mamdouhameen90 @notechnicals @chris83489710
Top assets mentioned SuperRare (RARE)
Top Social Posts
Top posts by engagements in the last XX hours
"$AKBA The Q32 Bio version of the announcement of the sale of ADX-097 had a few more details: "Akebia has acquired ADX-097 and will be responsible for future development and commercialization. Under the terms of the agreement Q32 Bio will receive $XX million in upfront payments and a near-term milestone which includes $X million received at signing $X million at the 6-month anniversary of signing and $X million payable upon the earlier of the achievement of a milestone or the end of 2026. These payments as well as potential development regulatory and commercial milestones total up to $592"
X Link 2025-12-01T14:46Z XXX followers, XXX engagements
"$AKBA Why acquire ADX-097 given the expenses Here is what I expect them to convey related to funding: We want to continue developing new kidney disease drugs. At this junction we do not have large amounts of capital. ADX-097 was sold to us at a low price. Research expenses will be modest in 2026. What helps keep those expenses low is that the FDA does not require large sample sizes for rare diseases. This drug may have some application to conditions that are not rare but that will not be our initial focus"
X Link 2025-12-01T16:22Z XXX followers, XXX engagements
"$KURA Cash vs. Market Cap At last quarterly reported $XXXXX million in cash. Today announced a $XXX million payment from Kyowa Kirin. Market Cap is about XXX million"
X Link 2025-12-02T18:21Z XXX followers, XXX engagements
"$RARE $MREO Timeline for Data Unchanged Data release: "Around end of year - defined as December or January""
X Link 2025-12-02T20:19Z XXX followers, XXX engagements
"$CRDF Results from Investigator-led (not company) Trial Positive monotherapy results yet the future will likely focus on use in combo treatment"
X Link 2025-12-08T21:19Z XXX followers, XXX engagements